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Abstract
Background and objective Dysferlinopathies are a
group of muscle disorders caused by mutations in the
DYSF gene. Previous muscle imaging studies describe
a selective pattern of muscle involvement in smaller
patient cohorts, but a large imaging study across the
entire spectrum of the dysferlinopathies had not been
performed and previous imaging findings were not
correlated with functional tests.
Methods We present cross-sectional T1-weighted
muscle MRI data from 182 patients with genetically
confirmed dysferlinopathies. We have analysed the
pattern of muscles involved in the disease using
hierarchical analysis and presented it as heatmaps.
Results of the MRI scans have been correlated with
relevant functional tests for each region of the body
analysed.
Results In 181 of the 182 patients scanned, we
observed muscle pathology on T1-weighted images, with
the gastrocnemius medialis and the soleus being the
most commonly affected muscles. A similar pattern of
involvement was identified in most patients regardless
of their clinical presentation. Increased muscle pathology
on MRI correlated positively with disease duration and
functional impairment.
Conclusions The information generated by this study
is of high diagnostic value and important for clinical
trial development. We have been able to describe a
pattern that can be considered as characteristic of
dysferlinopathy. We have defined the natural history
of the disease from a radiological point of view. These
results enabled the identification of the most relevant
regions of interest for quantitative MRI in longitudinal
studies, such as clinical trials.
Clinical trial registration NCT01676077.

Introduction

Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by mutations in
the DYSF gene.1 2 The absence or deficiency of
dysferlin leads to muscle fibre necrosis and replacement by fat and fibrous tissue. The two most
frequent presentations are limb girdle muscular
dystrophy type 2B (LGMD-2B) and distal myopathy with calf involvement or Miyoshi myopathy
(MM).3 Other phenotypes, such as distal myopathy
with anterior tibial involvement, proximodistal
weakness and pseudometabolic presentation, have
also been described.4 Clinical symptoms usually
start in young adulthood and are associated with
highly elevated serum creatine kinase levels. The
disease progresses invariably producing muscle
weakness that markedly impairs daily life activities.
Respiratory and cardiac involvement is uncommon
in patients with dysferlinopathy.5
In recent years, muscle MRI protocols have
been developed to assess disease progression in
muscular dystrophies using sequences that are
able to quantify the amount of fat replacement per
muscle.6 7 Previous muscle MRI studies in dysferlinopathy showed initial involvement of the adductor
magnus, semimembranosus and vastus lateralis
muscles in the thigh and gastrocnemius medialis,
soleus and tibialis anterior in the legs. The pattern
of muscle involvement has not been described to
vary between phenotypes, although these findings
were reported in small cohorts.8–11
Natural history studies are essential to understand
the progressive course of muscular dystrophies and
to identify suitable outcome measures that can be
used in future clinical trials. To address this gap,
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the Jain Foundation is funding The Clinical Outcome Study for
Dysferlinopathy, a multicentre natural history study in a large
cohort of patients (http://www.jain-foundation.org).12 Our aims
in this paper are to identify the pattern of muscle pathology
using MRI in a large cohort of patients with dysferlinopathy, to
identify which muscles might be suitable to assess by quantitative
MRI and study how MRI findings correlate with functional tests.

Methods
Study set-up and subjects

Functional status and physiotherapy assessment

Ambulation status was determined by the ability to walk 10 m
with shoes and usual walking aids or orthotics. Physiotherapists
assessed muscle strength in upper and lower limbs by manual
muscle testing (MMT) using an Medical Research Council
11-point scale (0=no movement, 1, 2, 3–, 3, 3+, 4–, 4, 4+,
5–, 5=no weakness). A dysferlinopathy-adapted 22-item scale
based on the original 17-item North Star Ambulatory Assessment (NSAA) scale used in Duchenne muscular dystrophy and
the Motor Function Measure were used to assess motor performance.12 13 Timed tests (6 min walk test, rise from floor, 10
m walk/run, time to climb and descend four steps and timed
up and go tests) were performed in ambulant patients. The
Brooke scale was performed to evaluate upper limb functional
status and the ACTIVLIM as a patient-reported outcome
measure.14 15

One hundred and eighty-two patients underwent a baseline
muscle MRI scan, of which 84 patients had whole body and
98 patients lower limb scans. The core protocol consisted of
T1-weighted, Dixon, B1 map and T2-weighted sequences. Here,
we report the findings using anatomical T1-weighted sequences.
The manufacturer, models and axial T1-weighted parameters are
detailed in online supplementary file 2. The quality of the MRI
studies was analysed by the study radiologists.
2

A blinded neurologist (RF-T) and radiologist (JL), both with
experience in muscle MRI in neuromuscular disorders, independently evaluated axial T1-weighted sequences with the semiquantitative Mercuri visual scale, modified by Fischer, described
in online supplementary file 2.16 The observers agreed on the
scoring of 96% of muscles. Inter-rater agreement kappa was
0.93 (95% CI 0.91 to 0.96). For the remaining 4%, observers
reviewed the muscles together and agreed a final score.

Genotype-MRI correlation

Two hundred and one patients with dysferlinopathy from 15
sites (Newcastle, Barcelona, Seville, Munich, Berlin, Padua,
Marseille, Paris, Saint Louis, Columbus, Charlotte, Washington
DC, Stanford, Tokyo and Sydney) were enrolled in the study.
One hundred and eighty-two patients had an MRI scan (clinical
and genetic details are described in online supplementary file
1). Inclusion criteria were ≥2 pathogenic mutations in DYSF or
1 pathogenic mutation plus either absent dysferlin expression
on skeletal muscle immunoblot or ≤20% blood dysferlin monocyte expression. Truncating mutations and splice site mutations
affecting the +1/–1 or +2/–2 positions were deemed pathogenic. Pathogenicity of other splice site mutations and missense
mutations was defined according to the UMD Predictor (http://
umd-predictor.eu).
Demographic data were collected for ethnicity, gender, age,
ambulatory status and disease duration. Patients were stratified according to the pattern of weakness at disease onset: (1)
LGMD-2B, (2) MM, (3) proximodistal weakness, (4) other
(pseudometabolic weakness). Those patients with no weakness
at baseline examination but hyperCKemia were considered as (5)
asymptomatic hyperCKemia. Disease duration was based on the
time from onset of muscle weakness in symptomatic patients and
time from first abnormal blood analysis result in patients with
isolated hyperCKemia.

Muscle MRI: acquisition

Muscle MRI: Semiquantitative assessment

We divided the cohort into two groups depending on mutation type: (1) patients in whom absent dysferlin expression was
predicted (harbouring homozygous or compound heterozygous truncating mutations) and (2) patients in whom reduced
dysferlin expression was predicted (two missense mutations
or one missense mutation and one truncating mutation). We
compared median value of muscle fatty replacement between
groups using the Wilcoxon-Mann-Whitney test.

Statistics

We used the Shapiro-Wilk test to confirm that none of our
variables were normally distributed. As such, non-parametric
statistic tests were used for the analysis.
The Mann-Whitney U test was used to compare quantitative
variables and the χ² test to compare qualitative variables. Due to
the high number of comparisons studied, Bonferroni correction
was used as posthoc analysis. To investigate correlations between
muscle function tests and MRI findings, Spearman’s rank
correlation was used (coefficient reported as ρ). The correlation
was considered significant if p value was less than 0.05 and ρ was
0.6 or higher. Hierarchical analysis and graphical representation
as a heatmap was performed using R software, V.3.1.3. Statistical
analyses were performed using IBM SPSS Statistics, V.21 (IBM,
Armonk, New York, USA).

Standard protocol approvals, registrations and patient
consents

All participants provided informed consent. The study was
approved by ethical review boards at each centre and registered
at ClinicalTrials.gov (NCT01676077).

Results
Patients

We included 182 patients (91 women, mean age at MRI
38±12.6 years) from whom we have obtained muscle MRI
scans. Demographic, clinical and genetic data are summarised in
online supplementary file 3.

Muscle MRI involvement: general features

Signal abnormalities in T1-weighted images were detected in all
but one patient (181 out of 182 patients). Asymmetric involvement, judged as a score difference of at least 2 points in at least
one muscle, was found in 77 patients (41.8%) although in 51/77
patients the asymmetry was found in one muscle only. Asymmetry in two or more muscles was found in 26/77 patients.
Muscles that had asymmetric involvement were variable.

Cranial muscles

Cranial involvement was analysed in 73 patients and fatty replacement was detected in 25 (34.2%). The tongue (34.2%) and
the cervical paraspinal muscles (24.6%) were most commonly
involved (figure 1A–D). In contrast, temporalis, masseter and
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Figure 1 Axial T1-weighted muscle MRI in dysferlinopathy. The cranial muscles (A–B) more commonly replaced by fat are the tongue (T) and the cervical
paraspinal muscles (CPs). Levator scapulae (LS) is generally not involved until later stages of the disease (C, no involvement; D, involvement). In the scapular
region (E–H) the subscapularis (Sc) is involved at the early stages; other muscles such as deltoid (De), infraspinatus (Is) or supraspinatus (SS) become
progressively involved. Rhomboideus (R) tends to be not involved until later stages of the disease (E–G, no involvement; H, involvement in an advanced
case). Biceps brachii (Bi), triceps brachii (Tr) and the anterior muscles of the forearm (FA) are commonly involved (I–K), while the posterior muscles of the
forearm (FP) are not involved even in later stages of the disease. Latissimus dorsi (LD) tends to be involved before serratus anterior (SA) in most of the
patients (I–J). Paraspinal muscles including the multifidus (M), the longissimus (L) and the iliocostalis (Ic) are affected in most of the patients at symptom
onset, while abdominal muscles, such as rectus abdominis (RA) are more resistant and become affected only in latter stages (K). Gluteus minor (GMi) is more
severely involved than gluteus medius (GMe) and maximus (GMa) (L–M). Pelvic floor muscles are transformed by fat in patients with dysferlinopathy, with
the tensor fascia latae (TFL), obturatorius externus (OE) and internus (OI) being the muscles more commonly involved (N–O). The posterior muscles of the
thighs (semimembranosus (Sm), biceps femoris long head (BLH), biceps femoris short head (BSH) or adductor major (AM)) are commonly involved in most of
the patients (P–S). BSH tend to be less involved than BLH in early and mid-stage patients (Q). Vasti muscles are commonly involved even in early stages of
the diseases (vastus intermedius (VI) in R). In contrast Sartorius (Sa) and gracilis (Gr) are not involved until late stages of the disease (Q and S). Analysis of
the lower legs (T–W) shows initial involvement of gastrocnemius medialis (GM) and lateralis (GL) and soleus (So). Peroneus muscles (Pe) are also involved in
most of the patients (U). Later in the progression of the disease tibialis anterior (TA) and posterior (TP) become transformed by fat (V–W).
sternocleidomastoideus muscles were least commonly affected
(only in 1, 2 and 3 patients, respectively). The degree of fat
replacement of the cervical paraspinal and sternocleidomastoideus

muscles had a statistically significant correlation with item 1 ‘lifts
head from supine’, from the NSAA-a, although the correlation
coefficient was poor (ρ=0.46) (table 1).
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Table 1 Correlation found between muscle MRI scores and the
appropriate muscle function test per every region of the body
Spearman
test

Correlation
coefficient

Body region

Functional score

Cranial muscles

NSAA item 1 (lift head)

0.0001

−0.46

Arm muscles

Brooke score

0.0001

0.77

MMT biceps*

0.0001

−0.68

Brooke scale

0.0001

0.68

ACTIVLIM scale

0.0001

−0.57

Scapular muscles
Trunk/pelvic
muscles
Thigh muscles

Leg muscles

Trunk, pelvis,
thigh muscles

Scapular muscles

NSAA item 12–13 (stand on one leg)

0.0001

−0.74

NSAA item 6 (get to sitting)

0.0001

−0.72

MMT glutei†

0.0001

−0.471

Time to Climb 4 Steps

0.0001

0.63

Time to Up & Go

0.0001

0.63

ACTIVLIM Up Stairs

0.0001

0.53

ACTIVLIM Down Stairs

0.0001

0.68

MMT knee flexion‡

0.0001

−0.63

NSAA item 20 (stand on heels)

>0.05

NSAA item 28 (stand on tiptoes)

>0.05

MMT plantar flexion§

>0.05

6MWT

0.0001

−0.73

Time to run/walk 10 m

0.0001

0.55

*Correlation between the degree of muscle fatty transformation of the biceps brachii and
the MMT of biceps.
†Correlation between mean degree muscle fatty transformation of the glutei muscles and
MMT of hip extension.
‡Correlation between the mean degree of muscle fatty transformation of the posterior
muscles of the thighs and MMT of knee flexion.
§Correlation between the mean degree of muscle fatty transformation of the posterior
muscles of the lower legs and MMT of plantar flexion.
MMT, manual muscle test; MWT, minute walking test; NSAA, North Star Ambulatory
Assessment.

Arm muscles

Arm involvement was analysed in 35 patients. Hierarchical
analysis identified two more commonly and severely involved
muscles (online supplementary figure 1A): the biceps brachii
(57.1%) and the anterior muscles of the forearm (53.8%).
Commonly observed patterns included:
1. The biceps brachii was equally or more severely involved
than the triceps or the brachialis muscles (figure 1I,J, online
supplementary figure 1 and table 2).
Table 2

2. The anterior muscles of the forearm were equally or more
severely involved than the posterior muscles of the forearm
(figure 1K and online supplementary figure 1).

Scapular involvement was analysed in 78 patients. Hierarchical analysis identified four muscles as more commonly and
severely involved (figure 2): the subscapularis (80.8%), latissimus dorsi (75.3%), infraspinatus (73.8%) and supraspinatus
(72.8%).
Commonly observed patterns included:
1. The subscapularis could be involved in patients even without
symptoms of proximal upper limb muscle dysfunction as
measured by the Brooke or MMT (figure 1E and figure 2).
2. The supraspinatus and infraspinatus were equally or more
severely involved than the rhomboideus (figure 1F–H and
figure 2).
3. The latissimus dorsi was equally or more severely involved
than the serratus anterior (figure 1I,J and figure 2).
4. If levator scapulae and rhomboideus were affected,
subscapularis, supraspinatus and infraspinatus were severely
involved (Mercuri 3–4) (figure 1C–H and figure 2).

Trunk and pelvic muscles

Trunk and pelvic involvement was analysed in 89 patients.
Hierarchical analysis identified six more commonly and more
severely involved muscles (online supplementary figure 2): the
tensor fascia latae (95%), gluteus minimus (90.8%), obturator
externus (86%), iliocostalis (93.1%), longissimus (86.2%) and
multifidus (88.5%).
Commonly observed patterns included:
1. Paraspinal muscles were equally or more involved than
abdominal muscles (figure 1J,K and online supplementary
figure 2).
2. The gluteus minimus was more severely involved than
gluteus medius and gluteus maximus (figure 1L,M and online
supplementary figure 2).
3. The obturator externus was equally or more severely
involved than the gluteus maximus (figure 1L–O and online
supplementary figure 2).

Percentage of patients for whom the every ‘pattern rule’ proposed was correct

Criteria

4

% of cases

Biceps brachii equally or more severely involved than the triceps

100

Biceps brachii equally or more severely involved than brachialis

97.05

Anterior muscles of the forearm more severely involved than posterior muscles of the forearm

95.05

Patients in which subscapularis was involved despite not having symptoms of proximal upper limb muscle dysfunction as measured by the Brooke test and the manual
muscle testing

67.64

The supraspinatus was equally or more severely involved than the rhomboideus

97.01

The infraspinatus was equally or more severely involved than the rhomboideus

98.38

The latissimus dorsi was equally or more severely involved than the serratus anterior

95.55

If levator scapulae and rhomboideus were affected, subscapularis, supraspinatus and infraspinatus were severely involved

77.77

Paraspinal muscles were equally or more involved than abdominal muscles

95.4

Gluteus minimus equally or more severely involved than gluteus medius

98.86

Gluteus minimus equally or more severely involved than gluteus maximus

95.45

Obturator externus equally or more severely involved than the gluteus maximus

89.87

Biceps femoris long head equally or more involved than the biceps femoris short head

95.18

Adductor magnus equally or more severely involved than the adductor longus

80.98

Rectus femoris (Score1 to 4) was not spared when the vasti muscles were involved (Score 2, 3 or 4)

92.61

Sartorius and gracilis were not completely replaced by fat

92.22

All symptomatic patients had involvement of at least one posterior muscle in the lower legs

100

Peroneus equally or more involved than the tibialis anterior

91.57
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Figure 2 Heatmaps showing involvement of scapular muscles. Patients and muscles are ordered according to hierarchical clustering with increasing
grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle
in a patient is indicated by the colour of the square. Grey squares mean that data are not available. The column in the top left contains information related
to the phenotype of the patient at onset of the disease (legend in the bottom left). We have also included a column with information about the time from
onset of symptoms to the MRI (years symptomatic) in blue and a column to the far right with the results of the Brooke and ACTIVLIM scales (see legends for
these scales at the bottom of the figure): the darker the square, the more time from onset (blue) or the worse the result of the Brooke (orange) or ACTIVLIM
scales. We found a statistically significant correlation between the median value of the Mercuri score per patient, the years symptomatic and the results of
the Brooke and ACTIVLIM scale. LGMD-2B, limb girdle muscular dystrophy type 2B.

Thigh muscles

Thigh involvement was analysed in 182 patients. Hierarchical
analysis identified four muscles that were more commonly
and more severely involved (figure 3): the semimembranosus
(95.4%), semitendinosus (90.2%), biceps femoris long head
(93.5%) and adductor magnus (94.1%).
Commonly observed patterns included:
1. The biceps femoris long head was equally or more involved
than the biceps femoris short head (figure 1P–S and figure 3).
2. The adductor magnus equally or more severely involved than
the adductor longus (figure 1P–S and figure 3).
3. Rectus femoris was not spared when the vasti muscles were
involved (Mercuri 2, 3 or 4) (figure 1P–S and figure 3).
4. The sartorius and gracilis were not involved until late stages,
but even then were not commonly completely replaced by fat
(figure 1P–S and figure 3).

Lower leg muscles

Lower leg involvement was analysed in 182 patients. Hierarchical analysis identified three more commonly and more

severely involved muscles (figure 4C): the soleus (99.45%),
gastrocnemius medialis (99.45%) and the gastrocnemius lateralis
(94.7%).
Commonly observed patterns included:
1. All symptomatic patients had involvement of at least one
posterior muscle of the lower legs (figure 1T–W and figure 4).
2. Peroneus equally or more involved than the tibialis anterior
(figure 1T–W and figure 4).
3. Patients with advanced disease could have involvement of all
lower leg muscles, including the tibialis posterior (figure 1T–
W and figure 4).

Influence of demographic and clinical features on muscle
involvement
There were gender differences in the degree of muscle fatty
involvement in some muscles. The rectus abdominis, rectus
femoris, vastus intermedius, vastus lateralis, vastus medialis, peroneus longus, peroneus brevis, gastrocnemius lateralis, gastrocnemius medialis and soleus were more severely
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Figure 3 Heatmap of the muscle involvement of the thigh muscles. Patients and muscles are ordered according to hierarchical clustering with increasing
grading in severity of fat replacement from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle
in a patient is indicated by the colour of the square. Grey squares means that data is not available. A column in the far left contains information related to
the phenotype of the patient at onset of the disease (Yellow: LGMD-2B; red: Miyoshi). We have also included a column with information about the time from
onset of symptoms to the MRI (years symptomatic) in blue and a column on the far right with the results of the Timed Up & Go and Time to Climb 4 Stairs
tests in red: the darker the square the more time from onset (blue) or the worse the result of the Time to Up & Go (red). We found a statistically significant
correlation between the median value of the Mercuri score per patient, the years symptomatic and the results of the time to Up & Go test. LGMD-2B, limb
girdle muscular dystrophy type 2; MMT, manual muscle testing.

involved in women (Mann Whitney U test, p<0.05).
Ethnicity did not appear to influence the degree of involvement. Neither the type of mutation nor the phenotype
at onset correlated with the pattern or severity of the fat
replacement on MRI.

Influence of disease duration on the degree of muscle
pathology: a natural history approach

Disease duration (defined here as time since onset of muscle
weakness) correlated with the degree of fat replacement in all
anatomical regions (Spearman’s test, p<0.0001). To investigate
the sequence of muscle involvement as the disease progressed,
we classified the patients into six groups depending on the
time to MRI from onset and calculated the median value of fat
replacement of muscle tissue. The heatmaps obtained revealed a
pattern of disease progression (figure 5). The muscles involved
in the earliest stages of the disease were predominantly in the
lower limbs, pelvis or trunk, although the subscapularis and
the latissimus dorsi could also be involved early (figure 5). The
rate at which fatty replacement progressed varied between
muscles, for example, the soleus, gastrocnemius medialis and
semimembranosus were usually completely involved after 10
years, while the adductor magnus or vastus lateralis were only
completely involved when disease duration approached 25
years.
6

Correlation between functional tests and the muscle Mercuri
score

The degree of fatty replacement on semiquantitative muscle
MRI was correlated with the Brooke scale for the upper limbs,
the 6 min walking test (6MWT) for the lower limbs and the
NSAA, MMT and timed tests (table 1).
For the scapular muscles, we classified the patients into five
groups according to the Brooke scale (the two least able scores
were grouped together and indicated by the number 5) and
calculated the median value of fat per muscle in every group
of patients. The heatmap obtained (online supplementary figure
3) showed that the subscapularis, latissimus dorsi, infraspinatus
and supraspinatus were involved in all patients, even if they were
in the most functional group (ie, score of 1), while the levator
scapulae or rhomboideus were only mildly involved, even in the
least able patients (score 4 and 5).
For the lower limbs, we classified patients into groups
depending on distance covered in the 6MWT and calculated
the median value of fat replacement for each muscle (figure 6).
Using this approach, we suggest which muscles would be
useful to follow longitudinally with muscle MRI according to
the result of the 6MWT. For example, in the case of patients
walking 600–700 m, the soleus, gastrocnemius medialis and the
peroneus group were already involved, though to a mild degree.
In contrast, these four muscles were completely transformed
in patients walking 300–400 m and would therefore not be
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Figure 4 Heatmap of the muscle involvement of the lower leg muscles. Patients and muscles are ordered according to hierarchical clustering with
increasing grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of
a muscle in a patient is indicated by the colour of the square. Grey squares means that data is not available. A column in the far left contains information
related to the phenotype of the patient at onset of the disease (Yellow: LGMD-2B; red: Miyoshi). We have also included a column with information about
the time from onset of symptoms to the MRI (years symptomatic) in blue. We found a statistically significant correlation between the median value of the
Mercuri score per patient and the years symptomatic. LGMD-2B, limb girdle muscular dystrophy type 2B.
suitable for follow-up once function has decreased to this level.
At this point, the graphic shows that the tibialis anterior, vastus
intermedius or even the vastus medialis would be more useful
for follow-up. In non-ambulant patients, the muscles useful
for follow-up included the gracilis, the gluteus medius or the
piriformis.

Discussion

We have characterised muscle involvement on MRI in a large
and clinically heterogeneous cohort of patients with dysferlinopathy. This large cross-sectional cohort has permitted better
characterisation of the pattern of muscle involvement in dysferlinopathy and improved our understanding of disease progression. This information will support both diagnostics and clinical
trial development.
We have defined a characteristic pattern of muscle involvement for dysferlinopathy, independent of the clinical phenotype. An early combination of fat replacement in distal posterior
muscles of the lower limbs (gastrocnemius medialis and soleus)
together with involvement of posterior muscles of the thighs
(semimembranosus, semitendinosus, adductor major), pelvic
muscles (tensor fascia latae and obturator externus), paraspinal
muscles (multifidus, iliocostalis) and the scapular muscles

(subscapularis and latissimus dorsi) can be helpful for differential diagnosis of patients with a muscle dystrophy and lead to
an early diagnosis of dysferlinopathy. Moreover, some muscles
are not involved until very late in the disease such as the levator
scapulae, the rhomboideus the posterior muscles of the forearms,
the gluteus maximus and medius muscles and the gracilis. This
pattern of muscle involvement and sparing could be helpful for
differential diagnosis by MRI in severely affected patients, in
whom obtaining a muscle biopsy may be challenging.
We confirmed that there are no differences in the pattern of
muscle involvement between patients with LGMD-2B, MM
or other phenotypic presentations.9–11 This suggests that these
subtypes of dysferlinopathy are not truly different and that a
unifying pathophysiology is likely, similar to findings in other
muscle diseases, such as the laminopathies, where different mutations result in similar patterns of selective muscle pathology.17
Extensive MRI investigations, rather than clinical descriptions,
are therefore more likely to be helpful in understanding the
pathophysiology of disease or the role of genetic modifiers. As
previously mentioned, some muscles were more involved in
women than men. Although we do not have a clear explanation to explain this issue, it is well known that testosterone and
estrogens influence skeletal muscle homeostasis and metabolism
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Figure 5 Heatmap showing the progression of the muscle involvement related to the time from onset of symptoms to the MRI. Patients were divided
into six groups for the analysis of the progression of muscle involvement. Muscles (columns) are ordered according to hierarchical clustering with increasing
grading of muscle fatty replacement in T1-W imaging from the left to the right. The score of a muscle per every group is indicated by the colour of the
square. We obtained a pattern of the progression of the disease related to the time from onset of symptoms to the MRI showing the natural history of the
disease.
and probably have an effect on muscle wasting in muscle dystrophies.18 Exercise has been shown to be important for muscle size
and metabolism, which may be a factor rather than gender here.
The pattern of muscle involvement reported here can be
considered characteristic for dysferlinopathy and contributes to
differential diagnosis between other muscle diseases with limb
girdle weakness. Patients with Becker muscular dystrophy tend
to have early fatty replacement of the glutei medius and maximus

while in contrast the adductor longus tends to be preserved until
later stages.18 19 Muscle MRI scans of patients with LGMD-1B
show no involvement of the vasti until later stages although the
rectus femoris tends not to be affected and is often hypertrophic.17 20 Patients with LGMD-2A tend to have more severe
involvement of the glutei and the vasti are less involved than
the posterior muscles of the thighs.21 22 This pattern is similar
in patients with LGMD-2I.23 Patients with sarcoglycanopathy,

Figure 6 Heatmap showing the progression of the muscle involvement related to the distance covered in the 6MWT. Patients were divided into eight
groups depending on the distance covered in the 6MWT for the analysis of the progression of muscle involvement. Muscles (columns) are ordered according
to hierarchical clustering with increasing grading of muscle fatty transformation in T1-W imaging from the left to the right. The score of a muscle per group
is indicated by the colour of the square. We obtained a pattern of the progression of the disease in muscles of the pelvis, thighs and lower legs related to the
functional test 6MWT.
8
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in whom there is usually no involvement of muscles of the
lower legs before loss of ambulation, are easy to distinguish.24
Patients with adult-onset Pompe, which presents frequently with
limb girdle weakness, have a muscle MRI pattern characterised
by early involvement of axial, abdominal, gluteal and posterior
thigh muscles, with the muscles of the lower legs not commonly
involved.25 26 Patients with mutation in ANO5 (LGMD-2L) have
a similar pattern of muscle involvement compared with patients
with dysferlinopathy, with predominant involvement of the
posterior muscles of the lower legs associated with involvement
of posterior and anterior muscles of the thighs without involvement of the glutei.27–29 However, some differences can be found:
the gluteus minimus and medius seem more commonly involved
in LGMD-2L than in LGMD-2B and asymmetric involvement is
more pronounced in LGMD-2L than dysferlinopathy.26 28
Previous similar radiological studies in dysferlinopathy
have been performed in lower limbs only and involved small
cohorts.9–11 30 Although these studies describe some of the
features found here, we have expanded the range of patients
analysed, using data from patients of different ethnic origins at
many different stages of the disease.
We presented the pathology scores from T1-weighted images as
heatmaps, as has been recently described for other muscle disorders.31 32 This is a new approach to display large amount of data,
which simplifies the analysis of several variables. Following this
method, we identified a clear correlation between disease duration and the degree of muscle involvement. This analysis raises
interesting questions about factors affecting the rate of muscle
degeneration. We showed that some muscles were involved early,
while others were not involved until much later. In addition,
while a group of muscles could become involved at the same
time, the progression of fat replacement between muscles in a
group could also vary. For example, in most patients, the gastrocnemius medialis becomes completely replaced by fat in less than
10 years from symptom onset, while the biceps femoris long
head, while also involved in the first 10 years, remains minimally
affected for longer. It is tempting to hypothesise that muscles
with a slower progression could express proteins that protect
them from rapid degeneration. Despite previous attempts to
investigate this in dysferlinopathy, it is still not clear why muscle
degeneration shows a different rate of progression.33 The clear
understanding of the pattern of severely involved and spared
muscles demonstrated here should allow for more focused investigations in the future.
T1-weighted muscle MRI has traditionally been used for
differential diagnosis of muscle diseases or to select a suitable
muscle to biopsy.34 35 As the development of novel therapeutics
for many muscular dystrophies progresses, there is a growing
need for reliable biomarkers to follow-up patients.36 We have
shown that muscle MRI findings correlate with the results of most
functional tests that may be included in clinical trials (table 1),
adding weight to its use as a biomarker. However, as dysferlinopathy is a slowly progressive disorder, changes from 1 year to the
next are probably not significant enough to be detectable using
semiquantitative T1w imaging. Quantitative sequences such as
3-point Dixon or T2-mapping should be more useful for patient
follow-up in short-term longitudinal studies.37–39 However, the
present study can inform longitudinal quantitative MRI studies
regards which muscles to monitor at different stages of disease.
This work is the result of a large international collaboration
between different clinical and radiological groups to harmonise
MRI protocols. However, although the study includes a high
number of patients with different phenotypes and different
disease stages, it has some obvious limitations. First, not all

patients were studied with whole body muscle MRI due to technical limitations in some centres. Second, the MRI systems used
were different, which can include some variability in the data
obtained. Third, there are no data regarding Short-TI Inversion
Recovery (STIR) results, but T2 imaging has been carried out
and scans are currently under analysis.
In summary, our study provides information about the distribution and degree of fat replacement of muscle tissue in the
largest cohort of patients with dysferlinopathy analysed to date.
The study has expanded the characterisation of patterns that can
be found in patients with dysferlinopathy, regardless of their
clinical phenotype. We have also shown a correlation between
muscle pathology as detected by MRI with disease duration
and the results of related functional tests, which will inform the
design of future clinical trials.
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